Abstract
Clozapine is used in the management of treatment‐resistant schizophrenia. However, its utility is limited by the occurrence of agranulocytosis, neutropenia, and leukopenia in up to 3% of patients, necessitating regular monitoring of hematological laboratory indices. In addition, several cases of self‐limiting eosinophilia have been reported in the literature, with most cases occurring 4 weeks after treatment initiation and rarely exceeding a 35% relative eosinophil count (percentage of white blood cells that are eosinophils).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
